STATINS: A NEW THERAPEUTIC APPROACH FOR THE TREATMENT OF NEUROPATHIC PAIN
DOI:
https://doi.org/10.22159/ijap.2024v16i5.50456Keywords:
HMG-CoA, Disease of somatosensory nerve, Neuropathic pain, StatinsAbstract
Due to a lesion or chronic illness state that affects the somatosensory nerve system, Neuropathic Pain (NP) is a terrible ailment. NP has recently been a top problem for the pharmaceutical and medical industries. For the therapy of NP, stains may offer an additional source of illumination. By preventing 3-Hydroxy-3-Methylglutaryl-Coenzyme a (HMG-CoA), it prevents the rate-limiting step in cholesterol production. HMG-CoA reductase inhibitors, which have a pleiotropic impact in addition to the cholesterol-lowering effects of statins, have also been linked to neuropathic pain. According to reports, statins can worsen endothelial dysfunction by making more nitric oxide available. Antioxidant, antiproliferative, and immunomodulatory activities are known to exist in it. It primarily comes highly suggested for cardiovascular issues and helps to reduce inflammation. Atherosclerotic plaque is under its control. To the best of our knowledge, this subject has not yet been the subject of clinical research in humans. Up until now, most of the evidence pointing to a connection between statins and neuropathic pain has been speculative. As a result, this evaluation should be considered a synopsis of what is already known, what is being investigated, and where more research might be needed. This review assesses the statins for neuropathic pain in preclinical as well as clinical research.
Downloads
References
St John Smith E. Advances in understanding nociception and neuropathic pain. J Neurol. 2018;265(2):231-8. doi: 10.1007/s00415-017-8641-6, PMID 29032407.
Gierthmuhlen J, Baron R. Neuropathic pain. Semin Neurol. 2016;36(5):462-8. doi: 10.1055/s-0036-1584950, PMID 27704502.
Siao P, Kaku M. A clinician’s approach to peripheral neuropathy. Semin Neurol. 2019;39(5):519-30. doi: 10.1055/s-0039-1694747, PMID 31639835.
Robertson AS. Disorders of the autonomic nervous system. Routledge; 2019.
Serhiyenko VA, Serhiyenko AA. Cardiac autonomic neuropathy: risk factors, diagnosis and treatment. World J Diabetes. 2018;9(1):1-24. doi: 10.4239/wjd.v9.i1.1, PMID 29359025.
Dieb W, Moreau N, Chemla I, Descroix V, Boucher Y. Neuropathic pain in the orofacial region: the role of pain history. A retrospective study. J Stomatol Oral Maxillofac Surg. 2017;118(3):147-50. doi: 10.1016/j.jormas.2017.03.004, PMID 28365394.
Yawn BP, Wollan PC, Weingarten TN, Watson JC, Hooten WM, Melton III LJ. The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population. Pain Med. 2009;10(3):586-93. doi: 10.1111/j.1526-4637.2009.00588.x, PMID 20849570.
Harifi G, Amine M, Ait Ouazar M, Boujemaoui A, Ouilki I, Rekkab I. Prevalence of chronic pain with neuropathic characteristics in the Moroccan general population: a national survey. Pain Med. 2013;14(2):287-92. doi: 10.1111/pme.12009, PMID 23241023.
Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain. 2006;7(4):281-9. doi: 10.1016/j.jpain.2005.11.008, PMID 16618472.
Bouhassira D, Lanteri Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136(3):380-7. doi: 10.1016/j.pain.2007.08.013, PMID 17888574.
Inoue S, Taguchi T, Yamashita T, Nakamura M, Ushida T. The prevalence and impact of chronic neuropathic pain on daily and social life: a nationwide study in a Japanese population. Eur J Pain. 2017;21(4):727-37. doi: 10.1002/ejp.977, PMID 28107599.
Van Acker K, Bouhassira D, De Bacquer D, Weiss S, Matthys K, Raemen H. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab. 2009;35(3):206-13. doi: 10.1016/j.diabet.2008.11.004, PMID 19297223.
Jacovides A, Bogoshi M, Distiller LA, Mahgoub EY, Omar MK, Tarek IA. An epidemiological study to assess the prevalence of diabetic peripheral neuropathic pain among adults with diabetes attending private and institutional outpatient clinics in South Africa. J Int Med Res. 2014;42(4):1018-28. doi: 10.1177/0300060514525759, PMID 24891556.
Jambart S, Ammache Z, Haddad F, Younes A, Hassoun A, Abdalla K. Prevalence of painful diabetic peripheral neuropathy among patients with diabetes mellitus in the Middle East region. J Int Med Res. 2011;39(2):366-77. doi: 10.1177/147323001103900204, PMID 21672340.
Beran R. Paraesthesia and peripheral neuropathy. Aust Fam Physician. 2015;44(3):92-5. PMID 25770571.
Sandkühler J. Models and mechanisms of hyperalgesia and allodynia. Physiol Rev. 2009;89(2):707-58. doi: 10.1152/physrev.00025.2008, PMID 19342617.
Cavalli E, Mammana S, Nicoletti F, Bramanti P, Mazzon E. The neuropathic pain: an overview of the current treatment and future therapeutic approaches. Int J Immunopathol Pharmacol. 2019;33:2058738419838383. doi: 10.1177/2058738419838383, PMID 30900486.
O’Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. 2009;122(10)Suppl:S22-32. doi: 10.1016/j.amjmed.2009.04.007, PMID 19801049.
Stevens D, Claborn MK, Gildon BL, Kessler TL, Walker C. Onasemnogene abeparvovec-xioi: gene therapy for spinal muscular atrophy. Ann Pharmacother. 2020;54(10):1001-9. doi: 10.1177/1060028020914274, PMID 32204605.
Niedzielski M, Broncel M, Gorzelak Pabis P, Woźniak E. New possible pharmacological targets for statins and ezetimibe. Biomed Pharmacother. 2020;129:110388. doi: 10.1016/j.biopha.2020.110388, PMID 32559626.
Pergolizzi JV, Magnusson P, LeQuang JA, Razmi R, Zampogna G, Taylor R. Statins and neuropathic pain: a narrative review. Pain Ther. 2020;9(1):97-111. doi: 10.1007/s40122-020-00153-9, PMID 32020545.
Grover HS, Luthra S, Maroo S. Are statins really wonder drugs? J Formos Med Assoc. 2014;113(12):892-8. doi: 10.1016/j.jfma.2013.05.016, PMID 24231094.
Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118. doi: 10.1146/annurev.pharmtox.45.120403.095748, PMID 15822172.
Kim SW, Kang HJ, Jhon M, Kim JW, Lee JY, Walker AJ. Statins and inflammation: new therapeutic opportunities in psychiatry. Front Psychiatry. 2019;10:103. doi: 10.3389/fpsyt.2019.00103, PMID 30890971.
Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5(4):378-87. doi: 10.1111/j.1582-4934.2001.tb00172.x, PMID 12067471.
Bhalla S, Singh N, Jaggi AS. Statins: do they aggravate or ameliorate neuropathic pain? J Pain. 2014;15(11):1069-80. doi: 10.1016/j.jpain.2014.06.012, PMID 25086324.
Fong CW. Statins in therapy: understanding their hydrophilicity, lipophilicity, binding to 3-hydroxy-3-methylglutaryl-CoA reductase, ability to cross the blood brain barrier and metabolic stability based on electrostatic molecular orbital studies. Eur J Med Chem. 2014;85:661-74. doi: 10.1016/j.ejmech.2014.08.037, PMID 25128668.
Ward NC, Watts GF, Eckel RH. Statin toxicity. Circ Res. 2019;124(2):328-50. doi: 10.1161/circresaha.118.312782, PMID 30653440.
Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19(1):117-25. doi: 10.1111/j.1472-8206.2004.00299.x, PMID 15660968.
Tsuda M. Microglia in the spinal cord and neuropathic pain. J Diabetes Investig. 2016;7(1):17-26. doi: 10.1111/jdi.12379, PMID 26813032.
Ekberg J, Craik DJ, Adams DJ. Conotoxin modulation of voltage-gated sodium channels. Int J Biochem Cell Biol. 2008;40(11):2363-8. doi: 10.1016/j.biocel.2007.08.017, PMID 17951097.
Ohsawa M, Ishikura KI, Mutoh J, Hisa H. Involvement of inhibition of RhoA/Rho kinase signaling in simvastatin-induced amelioration of neuropathic pain. Neuroscience. 2016;333:204-13. doi: 10.1016/j.neuroscience.2016.07.029, PMID 27457035.
Chen XY, Li K, Light AR, Fu KY. Simvastatin attenuates formalin-induced nociceptive behaviors by inhibiting microglial RhoA and p38 MAPK activation. J Pain. 2013;14(11):1310-9. doi: 10.1016/j.jpain.2013.05.011, PMID 23900131.
Li W, Li Y, Zhu S, Ji Q, Shu Y, Zhang L. Rosuvastatin attenuated the existing morphine tolerance in rats with L5 spinal nerve transection through inhibiting activation of astrocytes and phosphorylation of ERK42/44. Neurosci Lett. 2015;584:314-9. doi: 10.1016/j.neulet.2014.11.003, PMID 25445360.
Mukherjee P, Cinelli MA, Kang S, Silverman RB. Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain. Chem Soc Rev. 2014;43(19):6814-38. doi: 10.1039/c3cs60467e, PMID 24549364.
Miclescu A, Gordh T. Nitric oxide and pain: ‘Something old, something new’ Acta Anaesthesiol Scand. 2009;53(9):1107-20. doi: 10.1111/j.1399-6576.2009.02054.x, PMID 19702699.
Cinelli MA, Do HT, Miley GP, Silverman RB. Inducible nitric oxide synthase: regulation, structure, and inhibition. Med Res Rev. 2020;40(1):158-89. doi: 10.1002/med.21599, PMID 31192483.
Miranda HF, Noriega V, Olavarria L, Zepeda RJ, Sierralta F, Prieto JC. Antinociception and anti‐inflammation induced by simvastatin in algesiometric assays in mice. Basic Clin Pharmacol Toxicol. 2011;109(6):438-42. doi: 10.1111/j.1742-7843.2011.00746.x, PMID 21699658.
Pathak NN, Balaganur V, Lingaraju MC, Kant V, Latief N, More AS. Atorvastatin attenuates neuropathic pain in rat neuropathy model by down-regulating oxidative damage at peripheral, spinal and supraspinal levels. Neurochem Int. 2014;68:1-9. doi: 10.1016/j.neuint.2014.01.014, PMID 24513038.
Clark AK, Old EA, Malcangio M. Neuropathic pain and cytokines: current perspectives. J Pain Res. 2013;6:803-14. doi: 10.2147/JPR.S53660, PMID 24294006.
Hung AL, Lim M, Doshi TL. Targeting cytokines for treatment of neuropathic pain. Scand J Pain. 2017;17(1):287-93. doi: 10.1016/j.sjpain.2017.08.002, PMID 29229214.
Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett. 2004;361(1-3):184-7. doi: 10.1016/j.neulet.2003.12.007, PMID 15135924.
Chu LW, Chen JY, Yu KL, Cheng KI, Wu PC, Wu BN. Neuroprotective and anti-inflammatory activities of atorvastatin in a rat chronic constriction injury model. Int J Immunopathol Pharmacol. 2012;25(1):219-30. doi: 10.1177/039463201202500124, PMID 22507334.
Kim HK, Park SK, Zhou JL, Taglialatela G, Chung K, Coggeshall RE. Reactive oxygen species (ROS) play an important role in a rat model of neuropathic pain. Pain. 2004;111(1-2):116-24. doi: 10.1016/j.pain.2004.06.008, PMID 15327815.
Dai CQ, Guo Y, Chu XY. Neuropathic pain: the dysfunction of Drp1, mitochondria, and ROS homeostasis. Neurotox Res. 2020;38(3):553-63. doi: 10.1007/s12640-020-00257-2, PMID 32696439.
Yowtak J, Lee KY, Kim HY, Wang J, Kim HK, Chung K. Reactive oxygen species contribute to neuropathic pain by reducing spinal GABA release. Pain. 2011;152(4):844-52. doi: 10.1016/j.pain.2010.12.034, PMID 21296500.
Siniscalco D, Fuccio C, Giordano C, Ferraraccio F, Palazzo E, Luongo L. Role of reactive oxygen species and spinal cord apoptotic genes in the development of neuropathic pain. Pharmacol Res. 2007;55(2):158-66. doi: 10.1016/j.phrs.2006.11.009, PMID 17207636.
Gonçalves DO, Calou IB, Siqueira RP, Lopes AA, Leal LK, Brito GA. In vivo and in vitro anti-inflammatory and anti-nociceptive activities of lovastatin in rodents. Braz J Med Biol Res. 2011;44(2):173-81. doi: 10.1590/s0100-879x2011007500001, PMID 21243316.
Villegas Rivera G, Roman Pintos LM, Cardona Munoz EG, Arias Carvajal O, Rodriguez Carrizalez AD, Troyo Sanroman R. Effects of ezetimibe/simvastatin and rosuvastatin on oxidative stress in diabetic neuropathy: a randomized, double-blind, placebo-controlled clinical trial. Oxid Med Cell Longev. 2015;2015:756294. doi: 10.1155/2015/756294, PMID 26290682.
Bhalla S, Singh N, Jaggi AS. Dose-related neuropathic and anti-neuropathic effects of simvastatin in vincristine-induced neuropathic pain in rats. Food Chem Toxicol. 2015;80:32-40. doi: 10.1016/j.fct.2015.02.016, PMID 25726750.
Corso CR, Martins DF, Borges SC, Beltrame OC, Telles JE, Buttow NC. Effect of simvastatin on sensorial, motor, and morphological parameters in sciatic nerve crush induced-neuropathic pain in rats. Inflammopharmacology. 2018;26(3):793-804. doi: 10.1007/s10787-017-0425-1, PMID 29188473.
Qiu Y, Chen WY, Wang ZY, Liu F, Wei M, Ma C. Simvastatin attenuates neuropathic pain by inhibiting the RhoA/lIMK/cofilin pathway. Neurochem Res. 2016;41(9):2457-69. doi: 10.1007/s11064-016-1958-1, PMID 27216618.
Pathak NN, Balaganur V, Lingaraju MC, More AS, Kant V, Kumar D. Antihyperalgesic and anti-inflammatory effects of atorvastatin in chronic constriction injury-induced neuropathic pain in rats. Inflammation. 2013;36(6):1468-78. doi: 10.1007/s10753-013-9688-x, PMID 23872719.
Chu LW, Chen JY, Wu PC, Wu BN. Atorvastatin prevents neuroinflammation in chronic constriction injury rats through nuclear NFκB downregulation in the dorsal root ganglion and spinal cord. ACS Chem Neurosci 2015;6(6):889-98. doi: 10.1021/acschemneuro.5b00032, PMID 25874913.
Hasanvand A, Ahmadizar F, Abbaszadeh A, Amini-Khoei H, Goudarzi M, Abbasnezhad A. The antinociceptive effects of rosuvastatin in chronic constriction injury model of male rats. Basic Clin Neurosci. 2018;9(4):251-60. doi: 10.32598/bcn.9.4.251, PMID 30519383.
Miranda HF, Sierralta F, Aranda N, Poblete P, Castillo RL, Noriega V. Antinociception induced by rosuvastatin in murine neuropathic pain. Pharmacol Rep. 2018;70(3):503-8. doi: 10.1016/j.pharep.2017.11.012, PMID 29660653.
Peng Y, Zhang X, Zhang T, Grace PM, Li H, Wang Y. Lovastatin inhibits toll-like receptor 4 signaling in microglia by targeting its co-receptor myeloid differentiation protein 2 and attenuates neuropathic pain. Brain Behav Immun. 2019;82:432-44. doi: 10.1016/j.bbi.2019.09.013, PMID 31542403.
Ghayour MB, Abdolmaleki A, Rassouli MB. Neuroprotective effect of lovastatin on motor deficit induced by sciatic nerve crush in the rat. Eur J Pharmacol. 2017;812:121-7. doi: 10.1016/j.ejphar.2017.07.018, PMID 28688913.
Mirhadi K. Effect of intraperitoneally injection of different doses of lovastatin on pain and inflammatory response induced by formalin in mice. Am J Anim Vet Sci. 2011;6(4):160-5. doi: 10.3844/ajavsp.2011.160.165.
Zangiabadi N, Shafiee K, Alavi KH, Assadi AR, Damavandi M. Atorvastatin treatment improves diabetic polyneuropathy electrophysiological changes in non-insulin dependent diabetic patients: a double blind, randomized clinical trial. Minerva Endocrinol. 2012;37(2):195-200. PMID 22691892.
Hernandez Ojeda J, Roman Pintos LM, Rodriguez Carrizalez AD, Troyo-Sanroman R, Cardona Munoz EG, Alatorre Carranza Mdel P. Effect of rosuvastatin on diabetic polyneuropathy: a randomized, double-blind, placebo-controlled Phase IIa study. Diabetes Metab Syndr Obes. 2014;7:401-7. doi: 10.2147/DMSO.S65500, PMID 25214797.
Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med. 2014;161(10):711-23. doi: 10.7326/M14-0317, PMID 25199883.
Skiold LJ, Estefania RP, Carolina GM, Mery LR, Fernando CE, Jair LC. Synergistic interaction between B vitamins and statins to counter nociception in rats. Drug Dev Res. 2021;82(3):440-7. doi: 10.1002/ddr.21767, PMID 33305435.
de Souza LG, Hendler KG, Marcolino AM, Kuriki HU, Cardoso RB, de Cassia Registro Fonseca M. Photobiomodulation promotes neural regeneration when compared to simvastatin treatment in a sciatic nerve crush model. Lasers Med Sci. 2021;36(8):1591-7. doi: 10.1007/s10103-020-03176-y, PMID 33210186.
Mansouri MT, Khodayar MJ, Tabatabaee A, Ghorbanzadeh B, Naghizadeh B. Modulation of morphine antinociceptive tolerance and physical dependence by co-administration of simvastatin. Pharmacol Biochem Behav. 2015;137:38-43. doi: 10.1016/j.pbb.2015.08.002, PMID 26255154.
Ala S, Alvandipour M, Saeedi M, Hamidian M, Shiva A, Rahmani N. Effects of topical atorvastatin (2%) on posthemorrhoidectomy pain and wound healing: a randomized double-blind placebo-controlled clinical trial. World J Surg. 2017;41(2):596-602. doi: 10.1007/s00268-016-3749-x, PMID 27738832.
Venungopal P, Balakrishnan K, Sriram DK, George M. Inclisiran (Leqvio): a first-in-class small interfering rna therapeutic drug approved by Fda for treating primary hypercholesterolemia or dyslipidemia. Asian J Pharm Clin Res. 2022;15(12):42-6.
Singh P, Nanda A. Recent patents on solid dispersions of antihyperlipidemic drugs. Int J App Pharm. 2023;15(2):23-31. doi: 10.22159/ijap.2023v15i2.42402.
Kumar G, Pandey NK, Mishra V, Verma SP, Singh J, Kumar B. Optimization and characterization of microspheres of berberine hydrochloride using Box-Behnken design. Int J App Pharm. 2024;16(1):288-95. doi: 10.22159/ijap.2024v16i1.49254.
Dong W, Su X, Xu M, Hu M, Sun Y, Zhang P. Preparation, characterization, and in vitro/in vivo evaluation of polymer-assisting formulation of atorvastatin calcium based on solid dispersion technique. Asian J Pharm Sci. 2018;13(6):546-54. doi: 10.1016/j.ajps.2018.08.010, PMID 32211078.
Yusuf SM, Samparna S, Yallareddy K, Pavani B, Sivakala T. Analytical method development and validation of atorvastatin and clopidogrel in tablet dosage form by RP-HPLC. Eur J Pharm Med Res. 2017;4(4):553-8.
Gowtham T, Punitha S, Thrishala B, Soujanya P, Rajasekar S. Formulation and evaluation of atorvastatin calcium sustained release matrix tablets. Int J Res Pharm Sci. 2013;4(1):82-7.
Zhu KW, Wang GM, Li CY, Liu JY, Huang JY, Wu JR. Pharmacokinetics and bioequivalence of two formulations of rosuvastatin following single-dose administration in healthy Chinese subjects under fasted and fed conditions. Clin Pharmacol Drug Dev. 2022;11(8):987-96. doi: 10.1002/cpdd.1112, PMID 35567420.
Kishore CR, Mohan GV. Structural identification and estimation of rosuvastatin calcium related impurities in rosuvastatin calcium tablet dosage form. Anal Chem Res. 2017;12:17-27, doi: 10.1016/j.ancr.2016.11.002.
Sheraz MA, Ahsan SF, Khan MF, Ahmed S, Ahmad I. Formulations of Amlodipine: a review. J Pharm (Cairo). 2016;2016:8961621. doi: 10.1155/2016/8961621, PMID 27822402.
Norata GD, Tibolla G, Catapano AL. Statins and skeletal muscles toxicity: from clinical trials to everyday practice. Pharmacol Res. 2014;88:107-13. doi: 10.1016/j.phrs.2014.04.012, PMID 24835295.
Kyrklund C. Effects of gemfibrozil and rifampicin on the pharmacokinetics of HMG-CoA Reductase Inhibitors; 2004.
De Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta‐analysis. Pharmacotherapy. 2004;24(5):584-91. doi: 10.1592/phco.24.6.584.34738, PMID 15162892.
Published
How to Cite
Issue
Section
Copyright (c) 2024 INDU MELKANI, BIMLESH KUMAR, NARENDRA KUMAR PANDEY, DILEEP SINGH BAGHEL, SAURABH SINGH
This work is licensed under a Creative Commons Attribution 4.0 International License.
